Role of PACAP in migraine: An alternative to CGRP?
Migraine is a widespread and debilitating neurological condition affecting more than a billion people worldwide. Thus, more effective migraine therapies are highly needed. In the last decade, two endogenous neuropeptides, calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activat...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Neurobiology of Disease |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996122003382 |
| _version_ | 1797978320886824960 |
|---|---|
| author | Song Guo Inger Jansen-Olesen Jes Olesen Sarah Louise Christensen |
| author_facet | Song Guo Inger Jansen-Olesen Jes Olesen Sarah Louise Christensen |
| author_sort | Song Guo |
| collection | DOAJ |
| description | Migraine is a widespread and debilitating neurological condition affecting more than a billion people worldwide. Thus, more effective migraine therapies are highly needed. In the last decade, two endogenous neuropeptides, calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating peptide (PACAP), were identified to be implicated in migraine. Recently, introduction of monoclonal antibodies (mAbs) blocking the CGRP is the most important advance in migraine therapy for decades. However, 40% of patients are unresponsive to these new drugs. We believe that PACAP may be involved in these patients. Like CGRP, PACAP is located to sensory nerve fibers, it dilates cranial arteries, it causes migraine when infused into patients and it is a peptide that lends itself to antibody therapy. Also, recent studies suggest that the PACAP pathway is independent of the CGRP pathway. Understanding the signaling pathways of PACAP may therefore lead to identification of novel therapeutic targets of particular interest in patients unresponsive to anti-CGRP therapy. Accordingly, neutralizing mAb to PACAP is currently in clinical phase II development. The aim of the present review is, therefore, to give a thorough account of the existing data on PACAP, its receptors and its relation to migraine. |
| first_indexed | 2024-04-11T05:20:43Z |
| format | Article |
| id | doaj.art-eabac6584f354356b1ff1d5a902d3fff |
| institution | Directory Open Access Journal |
| issn | 1095-953X |
| language | English |
| last_indexed | 2024-04-11T05:20:43Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neurobiology of Disease |
| spelling | doaj.art-eabac6584f354356b1ff1d5a902d3fff2022-12-24T04:50:19ZengElsevierNeurobiology of Disease1095-953X2023-01-01176105946Role of PACAP in migraine: An alternative to CGRP?Song Guo0Inger Jansen-Olesen1Jes Olesen2Sarah Louise Christensen3Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DenmarkDepartment of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DenmarkDepartment of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DenmarkCorresponding author at: Danish Headache Center, Research Institute, Rigshospitalet Glostrup, Nordstjernevej 42, 2600 Glostrup, Denmark.; Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DenmarkMigraine is a widespread and debilitating neurological condition affecting more than a billion people worldwide. Thus, more effective migraine therapies are highly needed. In the last decade, two endogenous neuropeptides, calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating peptide (PACAP), were identified to be implicated in migraine. Recently, introduction of monoclonal antibodies (mAbs) blocking the CGRP is the most important advance in migraine therapy for decades. However, 40% of patients are unresponsive to these new drugs. We believe that PACAP may be involved in these patients. Like CGRP, PACAP is located to sensory nerve fibers, it dilates cranial arteries, it causes migraine when infused into patients and it is a peptide that lends itself to antibody therapy. Also, recent studies suggest that the PACAP pathway is independent of the CGRP pathway. Understanding the signaling pathways of PACAP may therefore lead to identification of novel therapeutic targets of particular interest in patients unresponsive to anti-CGRP therapy. Accordingly, neutralizing mAb to PACAP is currently in clinical phase II development. The aim of the present review is, therefore, to give a thorough account of the existing data on PACAP, its receptors and its relation to migraine.http://www.sciencedirect.com/science/article/pii/S0969996122003382PACAPCGRPMigraineDrug targetcAMP |
| spellingShingle | Song Guo Inger Jansen-Olesen Jes Olesen Sarah Louise Christensen Role of PACAP in migraine: An alternative to CGRP? Neurobiology of Disease PACAP CGRP Migraine Drug target cAMP |
| title | Role of PACAP in migraine: An alternative to CGRP? |
| title_full | Role of PACAP in migraine: An alternative to CGRP? |
| title_fullStr | Role of PACAP in migraine: An alternative to CGRP? |
| title_full_unstemmed | Role of PACAP in migraine: An alternative to CGRP? |
| title_short | Role of PACAP in migraine: An alternative to CGRP? |
| title_sort | role of pacap in migraine an alternative to cgrp |
| topic | PACAP CGRP Migraine Drug target cAMP |
| url | http://www.sciencedirect.com/science/article/pii/S0969996122003382 |
| work_keys_str_mv | AT songguo roleofpacapinmigraineanalternativetocgrp AT ingerjansenolesen roleofpacapinmigraineanalternativetocgrp AT jesolesen roleofpacapinmigraineanalternativetocgrp AT sarahlouisechristensen roleofpacapinmigraineanalternativetocgrp |